Phase 2 N=56 Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)
Anemia
Primary: Change in Left Ventricular End-diastolic Volume — -6; -4 mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=3,730 EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)
Heart Failure
Primary: Time to the First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF) — 21.00; 15.77 Patients with events/ 100 pt-yrs…
Phase 2 N=71 Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction
Heart Failure
Primary: Change in Left Ventricular End Systolic Volume (ml) — -4.4; -1.2; -3.8 mL
Phase 3 N=313 DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction
Heart Failure With Reduced Ejection Fraction (HFrEF)
Primary: Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 16 (Higher Scores Represent Less HF Symptom Frequency and…
N/A N=602 Heart Failure Optimization Study
Sudden Cardiac Death · Sudden Cardiac Arrest · Heart Failure
Primary: Percentage of Patients With LVEF Recovery at Day 90 and 180 — 222; 0; 0; 0 Participants
Phase 4 N=90 Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction
Heart Failure, Diastolic
Primary: Percent Change in Serum Creatinine at 72 Hours. — 4; 11; 5; 20 percent change in serum creatinine
Phase 3 N=6,263 Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.
Heart Failure With Preserved Ejection Fraction
Primary: Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure. — 512; 610 Participants — p=0.0008
N/A N=10 The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction
Primary: Change in Exercise Capacity at 6 Weeks — 659.9; 300.5 seconds — p=0.47
Phase 4 N=324 Dapagliflozin in PRESERVED Ejection Fraction Heart Failure
Chronic Heart Failure With Preserved Systolic Function
Primary: Effect of Dapagliflozin, as Compared With Placebo, on Heart Failure Related Health Status Using the Kansas City Cardiomyopathy Questionnaire Clinical Summary Summary…
Phase 3 N=5,050 A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)
Heart Failure · Chronic Heart Failure With Reduced Ejection Fraction
Primary: Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization — 33.6; 37.8 Parts w/ event per 100 part-yrs at risk…
Phase 3 N=6,105 A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)
Chronic Heart Failure With Reduced Ejection Fraction
Primary: Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization: Participants With an Event Per 100 Patient-Years…
Phase 3 N=6,016 Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%
Heart Failure
Primary: Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events — 1083; 1283 events — p=0.0072
Phase 2 N=35 Heart Failure Polypill at a Safety Net Hospital
Heart Failure With Reduced Ejection Fraction · HIV Infections
Primary: Measured Adherence to GDMT by Pill Count — 74.6; 83.3 adherence ratio expressed in %
Phase 2 N=26 Inhaled Sodium Nitrite on Heart Failure With Preserved Ejection Fraction
Heart Failure
Primary: Change in Pulmonary Capillary Wedge Pressure During Exercise — -1; -4 millimeters of mercury — p=0.002
Phase 4 N=37 Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction
Primary: Change in Plasma N-terminal Proatrial Natriuretic Peptide (NT proANP) — 47.4; 46.4 pg/mL
N/A N=349 A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients
Acute Decompensated Heart Failure
Primary: Short Physical Performance Battery (SPPB) at Month 3 — 6.9; 8.3 score on a scale — p=<0.0001
Phase 3 N=8,232 Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction
Heart Failure
Primary: Time to Cardiovascular Death or First Heart Failure Event — 39.1; 37.0 percentage of participants — p=0.0252
Phase 4 N=52 Effects of Aliskiren on Patient With Heart Failure and a Normal Ejection Fraction
Heart Failure
Primary: Exercise Treadmill Time — 621; 580; 624; 579 seconds — p=0.90
Phase 3 N=312 This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms
Heart Failure
Primary: Change From Baseline to Week 12 in Exercise Capacity as Measured by the 6-Minutes-Walking-Test (6MWT) Distance — 18.0; 13.5 Meter (m) — p=0.4236
Phase 3 N=2,278 RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Heart Failure · Anemia · Cardiovascular Disease
Primary: Time to All Cause Death or First Hospitalization for Worsening Heart Failure — 1260.0; 1184.0 days — p=0.871
Phase 2 N=34 ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure
Type 2 Diabetes Mellitus · Heart Failure
Primary: Fractional Excretion of Lithium (FELi) — 0.3; -2.3; 0.8; -4.9 percentage of filtered lithium excreted — p=0.36
N/A N=14 REmodeling the Left Ventricle With Atrial Modulated Pacing
Heart Failure
Primary: Number of Participants Who Remained on Study — 9; 4 participants
Phase 2 N=159 Study of Verinurad in Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction (HFpEF)
Primary: Change From Baseline at Week 32 in Peak V02 Consumption in Verinurad + Allopurinol Compared to Placebo (ANCOVA Model) — 0.27; 0.37 mL/kg/min — p=0.862
Phase 3 N=4,822 Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction
Primary: Cumulative Number of Primary Composite Events of Cardiovascular (CV) Death and Total (First and Recurrent) HF Hospitalizations. — 894; 1009; 690; 797 Events — p=0.0587
N/A N=27 REALIsM-HF Pilot Study
Heart Failure
Primary: Daily Steps Count — 5052; 3509; 6627; 2524 Steps
Phase 2 N=28 Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction
Heart Disease · Heart Failure With Preserved Ejection Fraction · Exercise Intolerance
Primary: Exercise Pulmonary Capillary Wedge Pressure (PCWP) — 19.0; 28.0 mm Hg — p=0.0003
Phase 4 N=55 Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF
Heart Failure, Diastolic · Diastolic Heart Failure · Hypertension
Primary: Coronary Flow Reserve — 2.64; 2.65; 2.06 ratio
Phase 3 N=121 Heart Rate Reduction in Heart Failure
Heart Failure
Primary: Exercise Tolerance Assessed by 6 Minute Walking Test — 474.8; 435.7; 453.1 meters
N/A N=335 Heart Failure Study: The Atlanta Cardiomyopathy Consortium
Heart Failure
Primary: Death, Heart Transplant, Left Ventricular Assist Device Implantation — 35 participants
N/A N=34,810 IMPROVE HF: Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting
Heart Failure, Congestive · Myocardial Infarction · Ventricular Dysfunction, Left
Primary: To Evaluate Over the Aggregate IMPROVE-HF Practice Sites the Relative Changes in 7 Performance Measures at 24 Months Compared With Baseline and Determine the Number of…